NASDAQ:CBIO Catalyst Biosciences (CBIO) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free CBIO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.34▼$7.6752-Week Range N/AVolume32,246 shsAverage Volume763,526 shsMarket Capitalization$291.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisDividendEarningsHeadlinesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisDividendEarningsHeadlinesOwnershipShort InterestSocial MediaSustainability Get Catalyst Biosciences alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Catalyst Biosciences Stock (NASDAQ:CBIO)Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… CBIO Stock News HeadlinesFebruary 10, 2024 | seekingalpha.comNeurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional UpsideJanuary 5, 2024 | markets.businessinsider.comBuy Rating Backed by Pivotal Trial Catalyst and Novel Drug Delivery Platform for Cellectar BiosciencesMarch 28, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!November 1, 2023 | businesswire.comBiocom California Names the Eighth Annual Life Science Catalyst Award WinnersOctober 30, 2023 | finance.yahoo.comCatalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock SplitOctober 23, 2023 | ft.comGeneral Catalyst in German VC tie-up as part of European tech pushOctober 18, 2023 | foxnews.com'Blind Side' author Michael Lewis suggests catalyst behind Michael Oher lawsuit: 'Violence and aggression'August 23, 2023 | finance.yahoo.comIs Catalyst Biosciences (CBIO) Significantly Overvalued?March 28, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!August 22, 2023 | investing.comCatalyst Biosciences (CBIO) Earnings Dates & ReportsJune 9, 2023 | finance.yahoo.comCBIO - Catalyst Biosciences, Inc.April 28, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHBI, CBIO, TA, ASRTApril 3, 2023 | finance.yahoo.comCatalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 monthsMarch 31, 2023 | insidermonkey.com5 Cheap Healthcare Stocks to Buy in 2023March 31, 2023 | markets.businessinsider.comRaymond James Sticks to Its Hold Rating for Catalyst Biosciences (CBIO)March 29, 2023 | finance.yahoo.com12 Cheap Healthcare Stocks to Buy in 2023March 9, 2023 | prnewswire.comCATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIOFebruary 28, 2023 | msn.comCatalyst Biosciences Shares Are Rallying: What's Driving The Action?February 28, 2023 | finance.yahoo.comCatalyst Biosciences Provides Corporate UpdateFebruary 27, 2023 | finance.yahoo.comGC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in HematologyFebruary 5, 2023 | morningstar.comCatalyst/Millburn Hedge Strategy IJanuary 19, 2023 | insidermonkey.com5 Stocks with the Lowest PE RatioJanuary 4, 2023 | prnewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Catalyst Biosciences, Inc. - CBIODecember 29, 2022 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Catalyst Biosciences, Inc. MergerDecember 29, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, BLI, ISO, CBIODecember 28, 2022 | benzinga.comCBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to ShareholdersNovember 16, 2022 | finance.yahoo.comCatalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)See More Headlines Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/17/2023Today3/28/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO CUSIP87611R30 CIK1124105 Webwww.catalystbiosciences.com Phone(650) 871-0761Fax336-480-2107Employees7Year Founded2003Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-364.68% Return on Assets-281.68% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual Sales$790,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.78) per share Price / BookN/AMiscellaneous Outstanding Shares37,980,000Free Float36,869,000Market Cap$291.29 million OptionableOptionable Beta1.05 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Nassim Usman Ph.D. (Age 63)President, CEO & Director Comp: $1.75MMs. Seline E. Miller CPA (Age 54)Senior VP of Finance, Interim Chief Financial & Principal Accounting Officer Comp: $707.55kMs. Ana KaporSenior Director of Investor Relations & Corporate CommunicationsKey CompetitorsVerastemNASDAQ:VSTMXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLVanda PharmaceuticalsNASDAQ:VNDAMerrimack PharmaceuticalsNASDAQ:MACKView All Competitors CBIO Stock Analysis - Frequently Asked Questions When is Catalyst Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our CBIO earnings forecast. How were Catalyst Biosciences' earnings last quarter? Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced its quarterly earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.07). When did Catalyst Biosciences' stock split? Catalyst Biosciences's stock reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Catalyst Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN). Who are Catalyst Biosciences' major shareholders? Catalyst Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. This page (NASDAQ:CBIO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.